SCHEMBL21895570

SCHEMBL21895570

CCCN(CCC)c1nc(OCCCN2CCOCC2)nc2c1CCC=CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HRH3 Q9Y5N1 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ SCN1A P35498 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ SCN2A Q99250 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ SCN3A Q9NY46 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TLR7 Q9NYK1 2/20 0.37
▸ CYP2D6 P10635 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22994702 0.83 ALDH1A1 (0.41) MAPK1ALDH1A1HRH3CYP1A2CHRM2
SCHEMBL19637387 0.74 HTR2A (0.43) MAPK1ALDH1A1HRH3CYP1A2CHRM2
SCHEMBL21895740 0.71 ALDH1A1 (0.41) MAPK1ALDH1A1HRH3CYP1A2CHRM2
SCHEMBL19637165 0.67 HRH3 (0.45) MAPK1ALDH1A1HRH3CYP1A2CHRM2
SCHEMBL14412522 0.64 CRHR1 (0.42) MAPK1ALDH1A1HRH3CYP1A2CHRM2
SCHEMBL14413070 0.63 CRHR1 (0.44) MAPK1ALDH1A1HRH3CYP1A2CHRM2
SCHEMBL21912197 0.61 HPGD (0.32) HRH3KCNH2TLR7
Pramoxine SCHEMBL26020 0.61 ALDH1A1 (1.00) MAPK1ALDH1A1HRH3CYP1A2CHRM2
Pramoxine SCHEMBL180542 0.60 LMNA (1.00) MAPK1ALDH1A1HRH3CYP1A2CHRM2
SCHEMBL23804878 0.60 HRH3 (0.91) MAPK1ALDH1A1HRH3CYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020055756-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2020-03-19 — — WO disclosed
Send feedback